Quest Diagnostics Given Consensus Recommendation of “Hold” by Analysts (NYSE:DGX)
Shares of Quest Diagnostics (NYSE:DGX) have received a consensus recommendation of “Hold” from the nineteen ratings firms that are currently covering the stock, AnalystRatings.NET reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $61.62.
Shares of Quest Diagnostics (NYSE:DGX) opened at 61.95 on Monday. Quest Diagnostics has a 52-week low of $50.46 and a 52-week high of $64.10. The stock has a 50-day moving average of $61.25 and a 200-day moving average of $58.14. The company has a market cap of $8.946 billion and a P/E ratio of 11.73.
Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.08 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.06 by $0.02. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. On average, analysts predict that Quest Diagnostics will post $4.05 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, October 22nd. Stockholders of record on Tuesday, October 7th will be paid a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a dividend yield of 2.13%. The ex-dividend date is Friday, October 3rd.
DGX has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday, August 1st. They now have a $64.00 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday, July 25th. They now have a $65.00 price target on the stock, up previously from $60.00. Finally, analysts at Maxim Group raised their price target on shares of Quest Diagnostics from $68.00 to $74.00 in a research note on Friday, July 25th. They now have a “buy” rating on the stock.
Quest Diagnostics Incorporated (NYSE:DGX) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.